KPV
Regulatory
Legal Status in 2026
No FDA approval for human use in the US; sold only as a research chemical.
This compound has no FDA approval for human use in the United States and is not available through licensed US pharmacies or compounding channels. It has not completed the clinical trials required for FDA approval. It may be sold online as a research chemical without quality controls, purity verification, or dosing standards. Always consult a physician.
About
About KPV
KPV is a tripeptide derived from the C-terminus of alpha-MSH (Lys-Pro-Val) with potent anti-inflammatory properties and direct antimicrobial activity. It is studied for inflammatory bowel disease, skin inflammation, and wound healing. Oral formulations show efficacy in gut inflammation by acting directly on intestinal epithelial cells and immune cells. It has a favorable safety profile.
Science
Mechanism of Action
Inhibits nuclear translocation of NF-κB and downregulates pro-inflammatory cytokine production (IL-6, TNF-α) in macrophages and epithelial cells; also activates melanocortin receptors to produce broad anti-inflammatory signaling.
Dosing
Typical Protocol
500 mcg–1 mg oral capsule daily for GI inflammation; 100–500 mcg subcutaneous injection for systemic use.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Availability
Provider availability
KPV has no FDA approval for human use and is not available through licensed US prescribing or compounding channels, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.